Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,140,999
  • Shares Outstanding, K 104,110
  • Annual Sales, $ 482,380 K
  • Annual Income, $ 106,140 K
  • 60-Month Beta 0.50
  • Price/Sales 6.74
  • Price/Cash Flow 32.92
  • Price/Book 5.99
Trade CORT with:

Options Overview Details

View History
  • Implied Volatility 77.07% ( +9.60%)
  • Historical Volatility 51.95%
  • IV Percentile 69%
  • IV Rank 46.41%
  • IV High 156.92% on 05/17/24
  • IV Low 7.91% on 06/05/23
  • Put/Call Vol Ratio 1.55
  • Today's Volume 4,425
  • Volume Avg (30-Day) 3,293
  • Put/Call OI Ratio 1.65
  • Today's Open Interest 68,251
  • Open Int (30-Day) 69,178

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.22
  • Number of Estimates 4
  • High Estimate 0.28
  • Low Estimate 0.20
  • Prior Year 0.25
  • Growth Rate Est. (year over year) -12.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.60 +33.50%
on 05/01/24
32.83 -8.10%
on 05/28/24
+6.85 (+29.37%)
since 04/30/24
3-Month
20.84 +44.77%
on 04/22/24
32.83 -8.10%
on 05/28/24
+6.67 (+28.38%)
since 02/29/24
52-Week
20.84 +44.77%
on 04/22/24
34.28 -11.98%
on 09/14/23
+6.19 (+25.81%)
since 05/26/23

Most Recent Stories

More News
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024

Stocks that traded heavily or had substantial price changes on Tuesday: Insmed, Agios rise; DraftKings, Atlantica fall

CORT : 30.17 (-3.33%)
ET : 15.67 (+0.84%)
USM : 55.46 (+9.35%)
AY : 21.98 (-1.83%)
DKNG : 35.13 (-1.93%)
AGIO : 36.34 (-3.20%)
INSM : 55.05 (-3.39%)
Corcept: Q1 Earnings Snapshot

Corcept: Q1 Earnings Snapshot

CORT : 30.17 (-3.33%)
Corcept: Q4 Earnings Snapshot

Corcept: Q4 Earnings Snapshot

CORT : 30.17 (-3.33%)
Corcept Therapeutics, PNM Resources fall; Johnson & Johnson rise, Tuesday, 1/2/2024

Stocks that traded heavily or had substantial price changes on Tuesday: Corcept Therapeutics, PNM Resources fall; Johnson & Johnson rise

BIDU : 97.20 (-1.73%)
PBR-A : N/A (N/A)
PBR : 15.55 (+1.44%)
CORT : 30.17 (-3.33%)
PNM : 38.34 (+2.62%)
JNJ : 146.67 (+0.96%)
ASML : 960.35 (-0.60%)
Corcept: Q3 Earnings Snapshot

Corcept: Q3 Earnings Snapshot

CORT : 30.17 (-3.33%)
Corcept: Q2 Earnings Snapshot

Corcept: Q2 Earnings Snapshot

CORT : 30.17 (-3.33%)
Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance

Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.

MRK : 125.54 (+0.81%)
CORT : 30.17 (-3.33%)
ALLO : 2.50 (+1.63%)
OCUP : 1.6800 (unch)
Corcept Therapeutics (CORT) Lags Q1 Earnings Estimates

Corcept (CORT) delivered earnings and revenue surprises of -30% and 1.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CORT : 30.17 (-3.33%)
TBPH : 8.62 (+1.53%)
Corcept: Q1 Earnings Snapshot

Corcept: Q1 Earnings Snapshot

CORT : 30.17 (-3.33%)
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More

Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.

UTHR : 275.13 (+1.73%)
PCRX : 30.33 (-0.43%)
AMRN : 0.8650 (+2.94%)
CORT : 30.17 (-3.33%)
IONS : 37.57 (+2.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 32.91
2nd Resistance Point 32.29
1st Resistance Point 31.23
Last Price 30.17
1st Support Level 29.55
2nd Support Level 28.94
3rd Support Level 27.88

See More

52-Week High 34.28
Last Price 30.17
Fibonacci 61.8% 29.14
Fibonacci 50% 27.56
Fibonacci 38.2% 25.97
52-Week Low 20.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar